These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 26340407)
1. Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth. Proietti CJ; Izzo F; Díaz Flaqué MC; Cordo Russo R; Venturutti L; Mercogliano MF; De Martino M; Pineda V; Muñoz S; Guzmán P; Roa JC; Schillaci R; Elizalde PV Mol Endocrinol; 2015 Oct; 29(10):1468-85. PubMed ID: 26340407 [TBL] [Abstract][Full Text] [Related]
2. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Diaz Flaqué MC; Vicario R; Proietti CJ; Izzo F; Schillaci R; Elizalde PV Steroids; 2013 Jun; 78(6):559-67. PubMed ID: 23178160 [TBL] [Abstract][Full Text] [Related]
3. Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. Proietti CJ; Béguelin W; Flaqué MC; Cayrol F; Rivas MA; Tkach M; Charreau EH; Schillaci R; Elizalde PV Steroids; 2011 Mar; 76(4):381-92. PubMed ID: 21184768 [TBL] [Abstract][Full Text] [Related]
4. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413 [TBL] [Abstract][Full Text] [Related]
5. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Proietti CJ; Rosemblit C; Beguelin W; Rivas MA; Díaz Flaqué MC; Charreau EH; Schillaci R; Elizalde PV Mol Cell Biol; 2009 Mar; 29(5):1249-65. PubMed ID: 19103753 [TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Béguelin W; Díaz Flaqué MC; Proietti CJ; Cayrol F; Rivas MA; Tkach M; Rosemblit C; Tocci JM; Charreau EH; Schillaci R; Elizalde PV Mol Cell Biol; 2010 Dec; 30(23):5456-72. PubMed ID: 20876300 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478 [TBL] [Abstract][Full Text] [Related]
8. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601 [TBL] [Abstract][Full Text] [Related]
9. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Gizard F; Robillard R; Gross B; Barbier O; Révillion F; Peyrat JP; Torpier G; Hum DW; Staels B Mol Cell Biol; 2006 Oct; 26(20):7632-44. PubMed ID: 17015480 [TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Díaz Flaqué MC; Galigniana NM; Béguelin W; Vicario R; Proietti CJ; Russo R; Rivas MA; Tkach M; Guzmán P; Roa JC; Maronna E; Pineda V; Muñoz S; Mercogliano M; Charreau EH; Yankilevich P; Schillaci R; Elizalde PV Breast Cancer Res; 2013 Dec; 15(6):R118. PubMed ID: 24345432 [TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492 [TBL] [Abstract][Full Text] [Related]
12. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Hawthorne VS; Huang WC; Neal CL; Tseng LM; Hung MC; Yu D Mol Cancer Res; 2009 Apr; 7(4):592-600. PubMed ID: 19372587 [TBL] [Abstract][Full Text] [Related]
13. Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells. Cuevas P; Díaz-González D; Sánchez I; Lozano RM; Giménez-Gallego G; Dujovny M Neurol Res; 2006 Mar; 28(2):127-30. PubMed ID: 16551428 [TBL] [Abstract][Full Text] [Related]
14. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. Catalano S; Giordano C; Rizza P; Gu G; Barone I; Bonofiglio D; Giordano F; Malivindi R; Gaccione D; Lanzino M; De Amicis F; Andò S J Cell Physiol; 2009 Mar; 218(3):490-500. PubMed ID: 18988190 [TBL] [Abstract][Full Text] [Related]
15. Integrity of the LXXLL motif in Stat6 is required for the inhibition of breast cancer cell growth and enhancement of differentiation in the context of progesterone. Wei M; He Q; Yang Z; Wang Z; Zhang Q; Liu B; Gu Q; Su L; Yu Y; Zhu Z; Zhang G BMC Cancer; 2014 Jan; 14():10. PubMed ID: 24401087 [TBL] [Abstract][Full Text] [Related]
16. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. Richer JK; Lange CA; Manning NG; Owen G; Powell R; Horwitz KB J Biol Chem; 1998 Nov; 273(47):31317-26. PubMed ID: 9813040 [TBL] [Abstract][Full Text] [Related]
17. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489 [TBL] [Abstract][Full Text] [Related]
18. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Proietti C; Salatino M; Rosemblit C; Carnevale R; Pecci A; Kornblihtt AR; Molinolo AA; Frahm I; Charreau EH; Schillaci R; Elizalde PV Mol Cell Biol; 2005 Jun; 25(12):4826-40. PubMed ID: 15923602 [TBL] [Abstract][Full Text] [Related]
19. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Menendez JA; Mehmi I; Lupu R Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820 [TBL] [Abstract][Full Text] [Related]
20. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]